These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 30019138)
1. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review. Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138 [TBL] [Abstract][Full Text] [Related]
2. The impact of patent expiry on drug prices: insights from the Dutch market. van der Schans S; Vondeling GT; Cao Q; van der Pol S; Visser S; Postma MJ; Rozenbaum MH J Mark Access Health Policy; 2020 Dec; 9(1):1849984. PubMed ID: 33312457 [No Abstract] [Full Text] [Related]
3. Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses. Serra-Burriel M; Martin-Bassols N; Perényi G; Vokinger KN JAMA Health Forum; 2024 Aug; 5(8):e242530. PubMed ID: 39150730 [TBL] [Abstract][Full Text] [Related]
4. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands. Boersma C; Klok RM; Bos JM; Naunton M; van den Berg PB; de Jong-van den Berg LT; Postma MJ Appl Health Econ Health Policy; 2005; 4(3):191-6. PubMed ID: 16309337 [TBL] [Abstract][Full Text] [Related]
5. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Magazzini L; Pammolli F; Riccaboni M Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754 [TBL] [Abstract][Full Text] [Related]
6. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. Roughead EE; Kim DS; Ong B; Kemp-Casey A WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668 [TBL] [Abstract][Full Text] [Related]
7. Does the market share of generic medicines influence the price level?: a European analysis. Dylst P; Simoens S Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288 [TBL] [Abstract][Full Text] [Related]
8. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Suh DC; Manning WG; Schondelmeyer S; Hadsall RS Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475 [TBL] [Abstract][Full Text] [Related]
9. Dynamics of price competition in Italian pharmaceutical off-patent market. Perna S; Cangini A; Marini R; Guerrizio MA; Da Cas R; Traversa G; Trotta F Front Med (Lausanne); 2022; 9():1045374. PubMed ID: 36523775 [TBL] [Abstract][Full Text] [Related]
10. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England. Mansfield SJ Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618 [TBL] [Abstract][Full Text] [Related]
11. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Clarke PM; Fitzgerald EM Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715 [TBL] [Abstract][Full Text] [Related]
12. [Impact of the expiry of the patent on quality and price of medicines at hospital: Study of five anticancer drugs from 2008 to 2015 at the Assistance publique-Hôpitaux de Paris]. Siorat V; Raybaut C; Poisson N; Paubel P Ann Pharm Fr; 2017 Jan; 75(1):59-66. PubMed ID: 27423185 [TBL] [Abstract][Full Text] [Related]
13. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators. Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710 [TBL] [Abstract][Full Text] [Related]
14. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Vogler S; Vitry A; Babar ZU Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089 [TBL] [Abstract][Full Text] [Related]
15. Analysis of Medicine Prices in New Zealand and 16 European Countries. Vogler S; Kilpatrick K; Babar ZU Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603 [TBL] [Abstract][Full Text] [Related]
16. International drug price comparisons: quality assessment. Machado M; O'Brodovich R; Krahn M; Einarson TR Rev Panam Salud Publica; 2011 Jan; 29(1):46-51. PubMed ID: 21390419 [TBL] [Abstract][Full Text] [Related]
17. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility. Lee SM; Kim HJ; Suh D; Joung KI; Kim ES; Back HJ; Kwon JY; Park MJ; Suh DC BMC Health Serv Res; 2021 Feb; 21(1):126. PubMed ID: 33549099 [TBL] [Abstract][Full Text] [Related]
18. The effect of generic competition on the price of brand-name drugs. Lexchin J Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552 [TBL] [Abstract][Full Text] [Related]
19. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335 [TBL] [Abstract][Full Text] [Related]
20. The diffusion of generics after patent expiry in Germany. Fischer KE; Stargardt T Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]